These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30286227)

  • 1. Association of Transient Colorblindness With Sildenafil and Tadalafil.
    Rosen SM; Kaja S; De Alba F
    JAMA Ophthalmol; 2019 Jan; 137(1):117-118. PubMed ID: 30286227
    [No Abstract]   [Full Text] [Related]  

  • 2. A Case Report: Consecutive Cranial Neuropathies Following the Use of Phosphodiesterase-5 Inhibitors.
    van Landingham SW; Singman EL
    Am Orthopt J; 2015; 65():109-14. PubMed ID: 26564936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Case of Recurrent Lobar Intracerebral Hemorrhage in the Setting of Phosphodiesterase-5 Inhibitor Use.
    Lucchese SA; Dhaliwal AS; Kaur A; Qi L
    Mo Med; 2019; 116(5):400-403. PubMed ID: 31645793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized clinical trial investigating treatment choice in Chinese men receiving sildenafil citrate and tadalafil for treating erectile dysfunction.
    Bai WJ; Li HJ; Jin JJ; Xu WP; Sebastian S; Wang XF
    Asian J Androl; 2017; 19(4):500-504. PubMed ID: 27101805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis.
    Hsu JC; Tang DH; Lu CY
    Int J Clin Pract; 2015 Apr; 69(4):436-43. PubMed ID: 25311239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis.
    Gong B; Ma M; Xie W; Yang X; Huang Y; Sun T; Luo Y; Huang J
    Int Urol Nephrol; 2017 Oct; 49(10):1731-1740. PubMed ID: 28741090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between sexual activity-related death and non-prescription use of phosphodiesterase type 5 inhibitors.
    Nagasawa S; Saka K; Yamagishi Y; Yajima D; Chiba F; Yamaguchi R; Torimitsu S; Iwase H
    Leg Med (Tokyo); 2021 Feb; 48():101815. PubMed ID: 33264696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major adverse cardiovascular events related to phosphodiesterase 5 inhibitors: analysis of real-life data from Eudra-Vigilance database.
    DE Nunzio C; Nacchia A; Grimaldi MC; Turchi B; Rovesti L; Franco A; Guarnotta G; Voglino O; Mancini E; Baldassarri V; Lombardo R; Cicione A; Tubaro A
    Minerva Urol Nephrol; 2024 Apr; 76(2):203-209. PubMed ID: 38498298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Central serous chorioretinopathy following the use of phosphodiesterase 5 inhibitors].
    Smal C; Lepièce G; Bonnet S
    Rev Med Liege; 2017 Nov; 72(11):475-477. PubMed ID: 29171944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fourth Cranial Nerve Palsy Associated With Sildenafil Citrate.
    Lee Y; Park KA; Oh SY; Min JH; Kim BJ
    J Neuroophthalmol; 2021 Mar; 41(1):e79-e80. PubMed ID: 32235216
    [No Abstract]   [Full Text] [Related]  

  • 11. [Current role of sildenafil in the management of erectile dysfunction].
    Akhvlediani ND; Matyukhov IP
    Urologiia; 2018 May; (2):142-146. PubMed ID: 29901310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PDE-5 inhibitors: clinical points.
    Doumas M; Lazaridis A; Katsiki N; Athyros V
    Curr Drug Targets; 2015; 16(5):420-6. PubMed ID: 25392015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction.
    Buvat J; Büttner H; Hatzimouratidis K; Vendeira PA; Moncada I; Boehmer M; Henneges C; Boess FG
    J Sex Med; 2013 Jun; 10(6):1592-602. PubMed ID: 23551622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Erectile dysfunction, PDE5A inhibitors and melanoma].
    Schmutz JL
    Ann Dermatol Venereol; 2015 Dec; 142(12):800-1. PubMed ID: 26293983
    [No Abstract]   [Full Text] [Related]  

  • 15. Risk-benefit considerations when prescribing phosphodiesterase-5 inhibitors in children.
    Magee AG; Makhecha S; Bentley S
    Expert Opin Drug Saf; 2015 May; 14(5):633-42. PubMed ID: 25746065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms underlie the proconvulsant effects of sildenafil.
    Zirak MR; Rahimian R; Mousavizadeh K; Dehpour AR
    Biomed Pharmacother; 2021 Feb; 134():111142. PubMed ID: 33360157
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of the therapeutic effects and side effects of tadalafil and sildenafil after surgery in young infants with pulmonary arterial hypertension due to systemic-to-pulmonary shunts.
    Sabri MR; Bigdelian H; Hosseinzadeh M; Ahmadi A; Ghaderian M; Shoja M
    Cardiol Young; 2017 Nov; 27(9):1686-1693. PubMed ID: 28994364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bilateral visual loss recovering after tadalafil withdrawal.
    Cordioli C; Capra R
    Neurol Sci; 2016 May; 37(5):809-10. PubMed ID: 26700798
    [No Abstract]   [Full Text] [Related]  

  • 19. [Phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: past, present and future].
    Gamidov SI; Ovchinnikov RI; Popova AY; Izhbaev SK
    Urologiia; 2017 Apr; (1):103-107. PubMed ID: 28394532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phosphodesterase type 5 inhibitors clinical efficiency and role in therapy for erectile dysfunction].
    Shodmonova ZR; Gafarov RR; Allazov SA; Giyasov SI
    Urologiia; 2021 May; (2):135-140. PubMed ID: 33960173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.